Persistent expression of CD26/DPPIV after treatment with infliximab in psoriasis despite clinical improvement

Acta Dermato-Venereologica

Volumn 89, Issue 5, 2009, Pages 518-520

  Van Lingen, Rosanne G ^a   Van Erp, Piet E J ^a   Seyger, Marieke M B ^a   De Jong, Elke M G J ^a   De Boer van Huizen, Roelie T ^a   Driessen, Rieke J B ^a   Van De Kerkhof, Peter C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; INFLIXIMAB;

ADULT; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMIS; DISEASE SEVERITY; EPIDERMIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; LETTER; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS VULGARIS; PUNCH BIOPSY; RATING SCALE; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD26; BIOPSY; DERMATOLOGIC AGENTS; FEMALE; HUMANS; KERATINOCYTES; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME;

EID: 70350144738     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0675     Document Type: Letter

References (10)

1. Kruger-Krasagakis S, Galanopoulos VK, Giannikaki L, Stefanidou M, Tosca AD. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis. Br J Dermatol 2006; 154: 460-466. (Pubitemid 43382653)
2. van Lingen RG, van de Kerkhof PC, Seyger MM, de Jong EM, van Rens DW, Poll MK, et al. CD26/dipeptidyl- peptidase IV in psoriatic skin: upregulation and topographical changes. Br J Dermatol 2008; 158: 1264-1272.
3. van Lingen RG, van de Kerkhof PC, de Jong EM, Seyger MM, Boezeman JB, van Erp PE. Reduced CD26bright expression of peripheral blood CD8+ T-cell subsets in psoriatic patients. Exp Dermatol 2008; 17: 343-348.
4. Bauvois B, Sanceau J, Wietzerbin J. Human U937 cell surface peptidase activities: characterization and degradative effect on tumor necrosis factor-alpha. Eur J Immunol 1992; 22: 923-930.
5. Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV Eur J Cell Biol 2003; 82: 53-73.
6. Salgado FJ, Vela E, Martin M, Franco R, Nogueira M, Cordero OJ. Mechanisms of CD26/dipeptidyl peptidase IV cytokine-dependent regulation on human activated lymphocytes. Cytokine 2000; 12: 1136-1141. (Pubitemid 30479501)
7. Bovenschen HJ, Seyger MM, van de Kerkhof PC. Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiation. Br J Dermatol 2005; 153: 72-78.
8. van Lingen RG, Poll MK, Seyger MM, de Jong EM, van de Kerkhof PC, van Erp PE. Distribution of dipeptidyl- peptidase IV on keratinocytes in the margin zone of a psoriatic lesion: a comparison with hyperproliferation and aberrant differentiation markers. Arch Dermatol Res 2008; 300: 561-567.
9. Bovenschen HJ, van Vlijmen-Willems IM, van de Kerkhof PC, van Erp PE. Identification of lesional CD4+ CD25+ Foxp3+ regulatory T cells in psoriasis. Dermatology 2006; 213: 111-117. (Pubitemid 44215194)
10. Jeffery CJ. Moonlighting proteins. Trends Biochem Sci 1999; 24: 8-11.